Consequently, focal dose escalation considering the individual geometric distribution of ITMs based on mpMRI and PSMA-PET might further improve oncological outcomes due to enhanced coverage of the intraprostatic tumor burden [11]. The gene discussed is FOLH1; the disease is neoplasm.